Validez diagnostica de los marcadores bioquímicos para el diagnóstico de Sarcopenia en personas adultas. Revisión sistemática
DOI:
https://doi.org/10.59856/arch.soc.chil.med.deporte.v63i2.32Palabras clave:
Biochemical Marker, Muscular Atrophy, muscle-Skeletal, sarcopenia, testosteroneResumen
Objetivo:
Evaluar la exactitud diagnóstica de la testosterona, hormona del crecimiento, factor de crecimiento insulínico tipo 1 (IGF-1), cortisol, miostatina, Interleuquina 6, 25-hidroxi-vitamina D, como marcadores biológicos para la detección de Sarcopenia.
Material y Métodos
Se realizó una búsqueda sistemática, lenguaje libre, sinónimos y variaciones ortográficas en distintas bases de datos, así como en fuentes de literatura gris y consulta a expertos. Se extrajeron los datos y se evaluó el riesgo de sesgos, con la herramienta QUADAS-2. Se buscó extraer datos de los marcadores bioquímicos, que sirvan como prueba diagnóstica para Sarcopenia.
Discusión
En los artículos encontrados podemos decir que cada uno de los factores bioquímicos estudiados han podido tener alguna relación con algunos de los parámetros que se encuentran dentro del diagnóstico de Sarcopenia; sin embargo, no existe uno que tenga relación causal o pronostica con la definición integral de Sarcopenia.
Referencias
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S-1S.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23.
Curcio F, Ferro G, Basile C, Liguori I, Parrella P, Pirozzi F, et al. Biomarkers in sarcopenia: A multifactorial approach. Exp Gerontol. 2016;85:1-8.
Galus K, Kozak-Szkopek E. [Diagnosis, prevention and treatment of sarcopenia]. Pol Merkur Lekarski. 2011;30(178):274-6.
Nass R, Johannsson G, Christiansen JS, Kopchick JJ, Thorner MO. The aging population--is there a role for endocrine interventions? Growth Horm IGF Res.2009;19(2):89-100.
Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294-305.
Beenakker KG, Ling CH, Meskers CG, de Craen AJ, Stijnen T, Westendorp RG, et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev.2010;9(4):431-6.
van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276-82.
Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging (Milano). 2000;12(6):455-60.
Grimaldi AS, Parker BA, Capizzi JA, Clarkson PM, Pescatello LS, White MC, et al. 25(OH) vitamin D is associated with greater muscle strength in healthy men and women. Med Sci Sports Exerc. 2013;45(1):157-62.
Kim H, Hirano H, Edahiro A, Ohara Y, Watanabe Y, Kojima N, et al. Sarcopenia: Prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatr Gerontol Int. 2016;16 Suppl 1:110-22.
Snyder PJ. Low testosterone must explain diminished physical performance in the elderly--right? J Clin Endocrinol Metab. 2010;95(6):2634-5.
Kositsawat J, Barry LC, Kuchel GA. Creactive protein, vitamin D deficiency, and slow gait speed. J Am Geriatr Soc. 2013;61(9):1574-9.
Lee SG, Lee YH, Kim KJ, Lee W, Kwon OH, Kim JH. Additive association of vitamin D insufficiency and sarcopenia with low femoral bone mineral density in noninstitutionalized elderly population: the Korea National Health and Nutrition Examination Surveys 2009-2010. Osteoporos Int. 2013;24(11):2789-99.
Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57(5):M326-32.
Ko MJ, Yun S, Oh K, Kim K. Relation of serum 25-hydroxyvitamin D status with skeletal muscle mass by sex and age group among Korean adults. Br J Nutr. 2015;114(11):1838-44.
Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010;21(4):543-59.
Pereira LS, Narciso FM, Oliveira DM, Coelho FM, Souza DaG, Dias RC. Correlation between manual muscle strength and interleukin-6 (IL-6) plasma levels in elderly community-dwelling women. Arch Gerontol Geriatr. 2009;48(3):313-6.
Heaney JL, Phillips AC, Carroll D. Ageing, physical function, and the diurnal rhythms of cortisol and dehydroepiandrosterone. Psychoneuroendocrinology. 2012;37(3):341-9.
Legrand D, Adriaensen W, Vaes B, Matheï C, Wallemacq P, Degryse J. The relationship between grip strength and muscle mass (MM), inflammatory biomarkers and physical performance in community-dwelling very old persons. Arch Gerontol Geriatr. 2013;57(3):345-51.
Meng Y, Wu H, Yang Y, Du H, Xia Y, Guo X, et al. Relationship of anabolic and catabolic biomarkers with muscle strength and physical performance in older adults: a population-based cross-sectional study. BMC Musculoskelet Disord. 2015;16:202.
Auyeung TW, Kwok T, Leung J, Lee JS, Ohlsson C, Vandenput L, et al. Sleep Duration and Disturbances Were Associated With Testosterone Level, Muscle Mass, and Muscle Strength--A Cross-Sectional Study in 1274 Older Men. J Am Med Dir Assoc. 2015;16(7):630.e1-6.
Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafè M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab. 2003;284(3):E481-7.
Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6(5):343-8.
Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci. 2000;55(12):M709-15.
Yuki A, Ando F, Otsuka R, Shimokata H. Low free testosterone is associated with loss of appendicular muscle mass in Japanese community-dwelling women. Geriatr Gerontol Int. 2015;15(3):326-33.
Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr. 2004;80(2):496-503.
Chang SF. [Sarcopenia in the elderly: diagnosis and treatment]. Hu Li Za Zhi.2014;61(2):101-5.
koek. Cortisol effects on physical performance and muscle strength in men.: B3. 2010.
Lorenzo D. Sarcopenia in the elderly: clinical involvement and evaluation. 2006.
Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998;147(8):750-4.
Auyeung TW, Lee JS, Kwok T, Leung J, Ohlsson C, Vandenput L, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a crosssectional study in 1489 older men. Eur J Endocrinol. 2011;164(5):811-7.
Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, et al. Biomarkers of sarcopenia in clinical trialsrecommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3(3):181-90.
Visser M, Deeg DJ, Lips P, Amsterdam LAS. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab.2003;88(12):5766-72.
Kim MK, Baek KH, Song KH, Il Kang M, Park CY, Lee WY, et al. Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. J Clin Endocrinol Metab. 2011;96(10):3250-6.
Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64(11):1183-9.
Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care.2012;15(1):12-22.
Taekema DG, Ling CH, Blauw GJ, Meskers CG, Westendorp RG, de Craen AJ, et al. Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women. Eur J Endocrinol. 2011;164(2):189-96.
Payette H, Roubenoff R, Jacques PF, Dinarello CA, Wilson PW, Abad LW, et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old communityliving men and women: the Framingham Heart Study. J Am Geriatr Soc. 2003;51(9):1237-43.
Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119(6):526.e9-17.
Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3(3):145-8.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2018 Archivos de la Sociedad Chilena de Medicina del Deporte

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.